| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 0 | 14,070 | 36,980 | 28,950 | 0 |
| Sales Growth | -100.00% | -61.95% | +27.74% | unch | unch |
| Net Income | -81,580 | -84,690 | -26,510 | -18,750 | -19,170 |
| Net Income Growth | +3.67% | -219.46% | -41.39% | +2.19% | +5.29% |
Frequency Therapeutics Inc
(FREQ)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Frequency Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company's lead product candidate, FX-322, is in clinical development and is designed to regenerate auditory hair cells to restore hearing function in patients with sensorineural hearing loss. Frequency Therapeutics Inc. is headquartered in Woburn, Mass.